Is left ventricular relative wall thickness a predictor of 5-year mortality in patients with acute decompensated heart failure?

左心室相对壁厚能否预测急性失代偿性心力衰竭患者的5年死亡率?

阅读:1

Abstract

OBJECTIVES: Heart failure (HF) is a significant global health problem that continues to increase in prevalence, morbidity, and mortality, particularly in aging populations. Relative wall thickness (RWT), an echocardiographic parameter reflecting geometric remodeling of the heart, is easily measurable and may possess prognostic value. This study aimed to evaluate the predictive power of RWT for 5-year mortality in patients with HF. METHODS: In this retrospective observational analysis, a total of 232 individuals diagnosed with acute decompensated heart failure were enrolled. RWT values were calculated using echocardiographic measurements. In this single retrospective cohort, participants were stratified into two subgroups based on their 5-year survival status. Demographic, clinical, laboratory, and echocardiographic parameters were compared between these subgroups. RESULTS: After 5 years of follow-up, 133 patients had died. Patients in the mortality group were significantly older (p = 0.001). The mortality cohort demonstrated a higher prevalence of chronic renal failure, atrial fibrillation, and mitral regurgitation compared with survivors. Echocardiographically, elevated systolic pulmonary artery pressure (sPAP) was associated with mortality (p = 0.009). However, regression analysis did not find sPAP to be statistically significant [95% confidence interval (CI), hazard ratio: 1.047 (0.818-1.340), p:0.7)]. RWT values ​​did not show a significant difference between the groups (0.39 ± 0.13 compared to 0.37 ± 0.06; p = 0.225). Area under the curve for RWT was 0.50 (95% CI: 0.43-0.57), indicating poor predictive power. Kaplan-Meier analysis showed no significant difference in survival between RWT groups (log-Rank:0.984, p: 0.32). CONCLUSION: RWT has limited ability to predict 5-year mortality among patients with advanced stages of HF. Age emerged as the strongest independent predictor. RWT should be evaluated in conjunction with multiple clinical and laboratory parameters rather than in isolation when managing HF.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。